Inventiva ADR (IVA)

Inventiva ADR Aktie (IVA) Neueste Nachrichten

Inventiva annonce le dépôt de son Document d’Enregistrement Universel 2023 et de son Rapport Annuel 2023 (« Form 20-F »)

GlobeNewswire Inc.

Inventiva annonce la nomination d’Andre Turenne en tant qu’administrateur

GlobeNewswire Inc.

Inventiva publie ses résultats annuels 2023

GlobeNewswire Inc.

Inventiva announces the schedule of publication and presentation of its 2023 Full-Year Financial Results

GlobeNewswire Inc.

Inventiva announces positive results from the Phase II, LEGEND, Proof-of-Concept study combining lanifibranor with empagliflozin in patients with MASH/NASH and T2D

GlobeNewswire Inc.

Madrigal Pharmaceuticals Wins Approval for the First Drug Targeting the Multibillion-Dollar NASH Market. Is the Stock a Screaming Buy?

The Motley Fool

Inventiva to present the results of LEGEND Phase IIa combination trial with lanifibranor and empagliflozin in patients with MASH/NASH and T2D

GlobeNewswire Inc.

Inventiva annonce la reprise du screening dans l’étude clinique de Phase III, NATiV3, évaluant lanifibranor dans la NASH  

GlobeNewswire Inc.

Why DoorDash Shares Are Trading Lower By Around 12%? Here Are Other Stocks Moving In Friday's Mid-Day Session

Benzinga

Why The Trade Desk Shares Are Trading Higher By Around 19%; Here Are 20 Stocks Moving Premarket

Benzinga

Yelp Reports Q4 Results, Joins Roku, Dropbox And Other Big Stocks Moving Lower In Friday's Pre-Market Session

Benzinga

Inventiva publie ses informations financières préliminaires pour l’exercice fiscal 2023¹ et fait le point sur son étude clinique NATiV3

GlobeNewswire Inc.

Bilan semestriel du contrat de liquidité de la société Inventiva conclu avec Kepler Cheuvreux

GlobeNewswire Inc.

Inventiva annonce le tirage de la seconde tranche de 25 millions d'euros dans le cadre de son Contrat de Financement avec la Banque Européenne d'Investissement

GlobeNewswire Inc.

Inventiva announces the randomization of the first patient in China in the NATiV3 clinical trial and provides an update on its clinical development program

GlobeNewswire Inc.

Inventiva announces the positive recommendation of the third DMC of the Phase III clinical trial with lanifibranor in patients with NASH

GlobeNewswire Inc.

Inventiva reports 2023 Third Quarter Financial Information¹

GlobeNewswire Inc.